Cingulate Stock (NASDAQ:CING)
Previous Close
$6.02
52W Range
$1.80 - $187.20
50D Avg
$5.79
200D Avg
$22.37
Market Cap
$12.90M
Avg Vol (3M)
$3.94M
Beta
-0.89
Div Yield
-
CING Company Profile
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CING Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| BLCM | Bellicum Pharmaceuticals, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| DYAI | Dyadic International, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| IKT | Inhibikase Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| HILS | Tharimmune, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| GNLX | Genelux Corporation |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |